Zobrazeno 1 - 10
of 12
pro vyhledávání: '"Guohao Xia"'
Autor:
Zhiting Zhao, Luqing Zhao, Guohao Xia, Jianwei Lu, Bo Shen, Guoren Zhou, Fenglei Wu, Xiao Hu, Jifeng Feng, Shaorong Yu
Publikováno v:
Frontiers in Oncology, Vol 12 (2023)
BackgroundBevacizumab has played an important role in the systemic treatment of patients with advanced non-small-cell lung cancer (NSCLC) without gene mutation. In recent years, bevacizumab biosimilar has received marketing approval based on the resu
Externí odkaz:
https://doaj.org/article/3147c7e9b90d452db30532c728fe0d7b
Autor:
Guohao Xia, Jiayuan Huang, Jie Ni, Meng Song, Junling Zhang, Paul Hofman, Petros Christopoulos, Anna Grenda, Mengli Huang
Publikováno v:
Translational Lung Cancer Research. 12:637-646
Autor:
Zhiting Zhao, Luqing Zhao, Guohao Xia, Jianwei Lu, Bo Shen, Guoren Zhou, Jifeng Feng, Xiao Hu, Shaorong Yu
PurposeBevacizumab is important in the systemic treatment of patients with advanced non-small-cell lung cancer (NSCLC) without gene mutation. Bevacizumab biosimilar has received marketing approval based on the results of phase III clinical studies. I
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e9831d0b30b504f75f62ecd23ff4d965
https://doi.org/10.21203/rs.3.rs-1943971/v1
https://doi.org/10.21203/rs.3.rs-1943971/v1
Publikováno v:
J Thorac Dis
Background EGFR-mutated lung cancer poorly responded to anti-programmed death-1 (PD-1)/programmed death-ligand 1 (PD-L1) monotherapy. Whether patients with EGFR-mutated lung cancer can benefit from anti-PD-1/PD-L1 therapy combined with other drugs re
Autor:
Qi Wang, Qingyou Liu, Ruijin Hong, Zhaoxia Han, Tingting Liu, Dawei Zhang, Guohao Xia, Yikai Jiang, Chunxian Tao, Hui Lin
Publikováno v:
Journal of Materials Science. 56:9871-9882
In this paper, Cu2O/Ag/Cu2O nanocomposite films were obtained by controlling thermal oxidation Cu/Ag/Cu alloy films and then modified by laser irradiation under ambient condition. The effects of laser irradiation on the surface morphology, structure,
Publikováno v:
Cell Death & Disease
Cell Death and Disease, Vol 11, Iss 7, Pp 1-14 (2020)
Cell Death and Disease, Vol 11, Iss 7, Pp 1-14 (2020)
Lung adenocarcinoma (LUAD) is the main component of non-small-cell lung cancer (NSCLC) and causes a great health concern globally. The top priority of LUAD treatment is to deal with gefitinib resistance. Long non-coding RNAs are certified to modify g
Autor:
Ruijin Hong, Qi Wang, Qingyou Liu, Hui Lin, Chunxian Tao, Qianbing Cheng, Guohao Xia, Dawei Zhang, Zhaoxia Han, Yikai Jiang
Publikováno v:
Optical Materials. 122:111728
Silver (Ag) thin films decorated with carbon nanoparticles were achieved by ablating Ag/C thin film with an Nd:YAG fiber pulsed laser under the environmental conditions. The structure and optical properties of the Ag/C samples were investigated. In t
Publikováno v:
Journal of Thoracic Disease. 9:4947-4959
Background: Lung cancer is the most common tumor, and has the highest incidence and mortality rates among all malignant tumors. Since stromal cell derived factor-1 (SDF-1) and CXC chemokine receptor 4 (CXCR4) are specific to binding sites, they are m
Publikováno v:
Journal of Clinical Oncology. 39:e21193-e21193
e21193 Background: In the past 3 years, immunotherapy has revolutionized the treatment paradigm of advanced non–small cell lung cancer (NSCLC). Checkpoint inhibitors showed promising results in the treatment of patients with advanced NSCLC with imp